Xuezhong Yang

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen et al. · The Lancet Oncology · 2020 · 253 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Induction of caspase 8 by interferon gamma renders some neuroblastoma (NB) cells sensitive to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) but reveals that a lack of membrane TR1/TR2 also contributes to TRAIL resistance in NB.

Xuezhong Yang, Melinda S. Merchant, María Elena Romero et al. · PubMed · 2003 · 96 citations

Life Sciences, Cell Biology, Oncology +17

Interferon γ Enhances the Effectiveness of Tumor Necrosis Factor-Related Apoptosis–Inducing Ligand Receptor Agonists in a Xenograft Model of Ewing’s Sarcoma

Melinda S. Merchant, Xuezhong Yang, Fraia Melchionda et al. · Cancer Research · 2004 · 73 citations

Medicine, Oncology, Pharmacology +17

Molecular cloning and characterization of human Castor, a novel human gene upregulated during cell differentiation

Zhihui Liu, Xuezhong Yang, Fei Tan et al. · Biochemical and Biophysical Research Communications · 2006 · 56 citations · Full text

Life Sciences, Molecular Biology, Molecular Genetics +12

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) for initial therapy of newly diagnosed multiple myeloma (NDMM): Results of ENDURANCE (E1A11) phase III trial.

Shaji Kumar, Susanna Jacobus, Adam D. Cohen et al. · Journal of Clinical Oncology · 2020 · 31 citations

Medicine, Pharmacology, Pharmacotherapy +10